

Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)

Technology appraisal guidance

Published: 20 April 2022

www.nice.org.uk/guidance/ta785

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma. This is because Bristol Myers Squibb withdrew the evidence submission. We will review this decision if the company decides to make a submission.

Information

If NHS organisations wish to consider nivolumab with cabozantinib for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-4448-4

Accreditation

